Age-related macular degeneration is one of the most common causes of vision loss in older adults, affecting millions of people worldwide. While there is no cure, modern medicine offers ways to slow disease progression and preserve quality of life through both established therapies and promising new treatments being tested in research studies.

Understanding Your Treatment Goals for Macular Degeneration

When you receive a diagnosis of age-related macular degeneration, often shortened to AMD, it’s natural to feel worried about your future vision. However, understanding what treatment can and cannot do helps set realistic expectations. The main goal of treating this condition is not to restore vision that has already been lost, but rather to slow down the disease’s progression and help you maintain the vision you still have for as long as possible.^[1]

Treatment approaches depend heavily on which type of AMD you have and what stage the disease has reached. The two main forms are dry AMD, which progresses slowly over years, and wet AMD, which can cause rapid vision loss within weeks or months if left untreated. Because AMD is a progressive disease, meaning it typically worsens over time, early detection through regular eye exams becomes crucial even when you notice no symptoms.^[1][8]

Your age, overall health, family history, lifestyle factors like smoking, and the specific characteristics of your macular degeneration all influence which treatment path your doctor will recommend. Medical societies and eye care organizations have developed clinical guidelines based on decades of research to help doctors choose the most appropriate therapies for each patient’s situation. At the same time, researchers around the world continue investigating new treatments in clinical trials, offering hope for better options in the future.^[6]

Standard Treatment Approaches for AMD

Treatment for Dry AMD

Currently, medical treatment options for dry AMD are limited, especially in the early and intermediate stages. For these stages, doctors often recommend a specific combination of vitamins and minerals known as the AREDS2 formula. This supplement regimen was developed following large clinical studies that showed certain nutrients could decrease the risk of dry AMD progressing to more advanced stages.^[10]

The AREDS2 formula includes vitamin C, vitamin E, zinc, copper, and two plant compounds called lutein and zeaxanthin. These substances are thought to protect the retina from damage caused by aging and environmental factors. People with intermediate-stage dry AMD who take this combination daily may slow the development of late dry AMD or wet AMD. The supplements are available over the counter, but you should always discuss with your doctor before starting them, as they may interact with other medications or health conditions.^[10][13]

Beyond supplements, lifestyle changes play a major role in managing dry AMD. Doctors strongly advise patients to stop smoking, as tobacco use is one of the most significant risk factors for disease progression. Maintaining a healthy diet rich in dark leafy greens, colorful fruits and vegetables, and fish high in omega-3 fatty acids supports retinal health. Controlling blood pressure and cholesterol levels also helps protect your vision over time.^[15][21]

For advanced dry AMD with geographic atrophy (a condition where areas of the retina waste away), two new medications have recently been approved in the United States: Syfovre and Izervay. Both are given as eye injections either monthly or every other month. These drugs work by reducing inflammation in the eye, which researchers believe contributes to the progression of geographic atrophy. In clinical trials, these medications slowed the rate at which damage spread across the macula. However, they do not restore lost vision, and regulatory agencies in some countries, including the United Kingdom, have declined to approve them due to concerns about whether the benefits meaningfully improve patients’ daily functioning during the trial period.^[14]

Treatment for Wet AMD

Wet AMD treatment has been revolutionized over the past two decades with the development of anti-VEGF drugs. VEGF stands for vascular endothelial growth factor, a family of proteins in the body that regulate the growth of blood vessels. In wet AMD, abnormal blood vessels called choroidal neovascularization grow beneath the retina, where they can leak fluid and blood, causing rapid damage to the macula.^[6]

Anti-VEGF medications block these proteins, stopping the growth of abnormal blood vessels and preventing further leakage. This helps preserve vision and, in many cases, can even improve it. There are currently five anti-VEGF drugs used to treat wet AMD: Avastin (bevacizumab), Lucentis (ranibizumab), Eylea (aflibercept), Beovu (brolucizumab), and Vabysmo (faricimab).^[6]

These medications are delivered through injections directly into the eye, a procedure called intravitreal injection. Before the injection, your doctor applies numbing eye drops to minimize discomfort. Most patients report feeling only slight pressure during the procedure, which takes just a few seconds. While the idea of an eye injection may sound frightening, the process is generally well-tolerated and has become routine in eye care clinics.^[6]

Treatment typically begins with three monthly injections to stabilize the disease. After this initial phase, your doctor will choose one of three treatment schedules based on how your eyes respond. The “treat and extend” approach gradually increases the time between injections as long as the disease remains stable. The “pro re nata” or PRN approach means you receive injections only when needed based on signs of disease activity. Some patients require monthly injections indefinitely to maintain vision stability.^[6]

The side effects of anti-VEGF injections are usually mild and temporary. You might experience redness, mild discomfort, or a feeling of grittiness in the eye for a day or two afterward. Serious complications like infection or retinal detachment are rare but possible. Your doctor will monitor you closely and provide instructions on warning signs to watch for after each injection.^[6]

Before anti-VEGF drugs became available, wet AMD was treated with laser photocoagulation or photodynamic therapy (PDT). Laser photocoagulation uses a focused beam of light to seal leaking blood vessels, but it can also damage surrounding healthy tissue. Photodynamic therapy combines a light-sensitive drug injected into your bloodstream with a special laser that activates the drug only in the targeted area, causing less damage to healthy tissue. Today, these treatments are rarely used because anti-VEGF injections are far more effective at preserving vision.^[6][9]

Innovative Treatments Being Studied in Clinical Trials

While current treatments help many patients, researchers continue searching for better options, especially for dry AMD where treatment choices remain limited. Clinical trials test new drugs, devices, and approaches to determine if they are safe and effective before making them available to all patients.

Stem Cell Research

One promising area of investigation involves stem cell transplants for dry AMD. Stem cells are special cells that can develop into different types of tissue in the body. In these trials, researchers are testing whether transplanting stem cells into the eye can replace damaged cells in the retina and potentially restore some vision. Early-phase trials are evaluating the safety of this approach and looking for signs that it might work. If successful in these early studies, larger trials would follow to confirm effectiveness.^[1][8]

Complement System Inhibitors

The complement system is part of your immune system that helps fight infections, but in AMD, it may become overactive and contribute to inflammation and tissue damage in the retina. Scientists have developed drugs that inhibit or block parts of this system to reduce harmful inflammation. Syfovre and Izervay, the two medications recently approved in the United States for geographic atrophy, work through this mechanism. They target specific components of the complement system to slow disease progression.^[14]

Other complement inhibitors are still being tested in clinical trials at various stages. These studies typically enroll patients with advanced dry AMD or geographic atrophy. Phase I trials focus primarily on safety, determining whether the drug causes harmful side effects. Phase II trials begin to evaluate whether the drug actually slows disease progression by measuring changes in the size of affected areas in the retina. Phase III trials compare the new treatment against standard care or placebo in large groups of patients to definitively prove effectiveness.^[12]

Photobiomodulation

Photobiomodulation, also known as light therapy, uses specific wavelengths of light to stimulate cells in the retina. The theory is that certain types of light energy can improve cellular function and potentially slow the deterioration of retinal cells in dry AMD. Patients typically sit in front of a special light device for several minutes during treatment sessions. This approach is still experimental, and researchers are working to determine optimal light wavelengths, treatment duration, and frequency.^[10]

Improved Anti-VEGF Therapies

Even though anti-VEGF injections have transformed wet AMD treatment, researchers are working to make them even better. Some clinical trials are testing new anti-VEGF molecules that might last longer in the eye, reducing the number of injections needed. Others are investigating different ways to deliver these drugs, such as through slow-release implants placed inside the eye that can provide medication for several months without repeated injections. These innovations aim to reduce the treatment burden on patients while maintaining or improving outcomes.^[12]

Participating in Clinical Trials

Clinical trials are conducted at research centers, hospitals, and specialized eye clinics in many locations, including the United States, Europe, and other countries around the world. Each trial has specific requirements, called eligibility criteria, which determine who can participate. These criteria might include the type and stage of AMD you have, your age, other health conditions, and whether you’ve received previous treatments.^[1]

Participating in a clinical trial gives you access to cutting-edge treatments before they become widely available. You also receive close monitoring from medical experts throughout the study. However, it’s important to understand that experimental treatments may not work better than existing options, and some studies use placebo (inactive treatment) groups for comparison. Your doctor can help you find appropriate trials and discuss whether participation makes sense for your situation.^[1]

Most common treatment methods

• Nutritional supplements
  • AREDS2 formula containing vitamin C, vitamin E, zinc, copper, lutein, and zeaxanthin for intermediate dry AMD
  • Available over the counter but should be discussed with your doctor before starting
  • May slow progression to advanced stages of the disease
• Anti-VEGF injections
  • Primary treatment for wet AMD using drugs like Avastin, Lucentis, Eylea, Beovu, and Vabysmo
  • Injected directly into the eye to block abnormal blood vessel growth
  • Usually given monthly initially, then adjusted based on disease response
  • Can preserve and sometimes improve vision
• Complement inhibitors
  • Syfovre and Izervay approved in the United States for geographic atrophy (advanced dry AMD)
  • Eye injections given monthly or every other month
  • Reduce inflammation to slow progression of retinal damage
  • Do not restore lost vision
• Lifestyle modifications
  • Smoking cessation to reduce disease progression risk
  • Diet rich in leafy greens, colorful fruits and vegetables, and omega-3 fatty acids
  • Control of blood pressure and cholesterol levels
  • Wearing UV-protective sunglasses outdoors
• Photodynamic therapy
  • Light-sensitive drug injected into bloodstream combined with targeted laser treatment
  • Rarely used now due to superior effectiveness of anti-VEGF injections
  • May be considered in specific situations where anti-VEGF is not suitable
• Experimental therapies in clinical trials
  • Stem cell transplants being tested for dry AMD
  • Photobiomodulation (light therapy) under investigation
  • New complement inhibitors in various trial phases
  • Longer-acting anti-VEGF formulations and delivery systems